- Home
- SCNX vs ONCY Comparison
SCNX vs ONCY Comparison
Compare SCNX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- ONCY
- Stock Information
- Founded
- SCNX 2010
- ONCY 1998
- Country
- SCNX United States
- ONCY Canada
- Employees
- SCNX N/A
- ONCY N/A
- Industry
- SCNX Other Pharmaceuticals
- ONCY Pharmaceuticals and Biotechnology
- Sector
- SCNX Health Care
- ONCY Health Care
- Exchange
- SCNX Nasdaq
- ONCY Nasdaq
- Market Cap
- SCNX 65.4M
- ONCY 61.0M
- IPO Year
- SCNX 2020
- ONCY 1999
- Fundamental
- Price
- SCNX $3.90
- ONCY $0.73
- Analyst Decision
- SCNX
- ONCY Strong Buy
- Analyst Count
- SCNX 0
- ONCY 2
- Target Price
- SCNX N/A
- ONCY $4.00
- AVG Volume (30 Days)
- SCNX 10.8K
- ONCY 2.6M
- Earning Date
- SCNX 02-10-2025
- ONCY 03-06-2025
- Dividend Yield
- SCNX N/A
- ONCY N/A
- EPS Growth
- SCNX N/A
- ONCY N/A
- EPS
- SCNX 3.55
- ONCY N/A
- Revenue
- SCNX N/A
- ONCY N/A
- Revenue This Year
- SCNX $1,085.75
- ONCY N/A
- Revenue Next Year
- SCNX N/A
- ONCY N/A
- P/E Ratio
- SCNX $1.68
- ONCY N/A
- Revenue Growth
- SCNX 166.67
- ONCY N/A
- 52 Week Low
- SCNX $3.48
- ONCY $0.71
- 52 Week High
- SCNX $44.56
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- ONCY 36.48
- Support Level
- SCNX N/A
- ONCY $0.73
- Resistance Level
- SCNX N/A
- ONCY $0.90
- Average True Range (ATR)
- SCNX 0.00
- ONCY 0.06
- MACD
- SCNX 0.00
- ONCY -0.01
- Stochastic Oscillator
- SCNX 0.00
- ONCY 11.35
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.